INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5
INmune Bio (NASDAQ: INMB) will host a conference call on May 5, 2021, at 4:30 PM ET, to discuss its first-quarter results for the period ending March 31, 2021, and provide a corporate update. The call can be accessed by dialing 1-877-407-0784 (or 1-201-689-8560 for international callers). A transcript will be available shortly after the call, with a replay accessible until May 12, 2021.
INmune Bio focuses on developing treatments targeting the innate immune system for various diseases.
- The upcoming conference call provides an opportunity for stakeholders to gain insights into the company's financial performance and strategic direction.
- None.
Management to host conference call at 4:30 pm ET on that day
LA JOLLA, Calif, April 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Wednesday, May 5, 2021 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2021 and to provide a corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching an operator.
Date: May 5, 2021
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-877-407-0784
Participant Dial-in (international): 1-201-689-8560
A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through Wednesday, May 12, 2021 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 13718747.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com
Investor Contact:
Chuck Padala
LifeSci Advisors, LLC
(917) 741-7792
Chuck@lifesciadvisors.com
FAQ
When will INmune Bio announce its first quarter results for 2021?
How can I participate in the INmune Bio conference call?
What time is the INmune Bio conference call scheduled?
Will there be a replay of the INmune Bio conference call?
